The coronavirus variant first identified in South Africa is better at “breaking through” the defences of the Pfizer/BioNTech vaccine than other forms of the virus.
This is according to Israeli experts.
However, one of the authors told AFP that while the study showed the variant to be relatively successful in infecting vaccinated people, it did not provide any data on whether it could generate serious illness among vaccinees.
The study by Tel Aviv University and Clalit Health Services, Israel’s largest healthcare provider, compared 400 unvaccinated people infected with COVID-19 to 400 partially or fully vaccinated people who also had the virus.
According to the study, published as a draft on Saturday and currently being peer reviewed, the variant discovered in South Africa accounted for less than one percent of coronavirus cases in Israel.